预约演示
更新于：2026-10-21
Pyridostigmine Bromide
溴吡斯的明
更新于：2026-10-21
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1955-04-06), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C9H13BrN2O2 |
InChIKeyVNYBTNPBYXSMOO-UHFFFAOYSA-M |
CAS号101-26-8 |
关联
77
项与 溴吡斯的明 相关的临床试验CTR20262309
溴吡斯的明片（60mg）在健康试验参与者中空腹给药条件下随机、开放、单剂量、两制剂、两序列、两周期、双交叉生物等效性预试验
CTR20262306
溴吡斯的明片在中国健康试验参与者空腹状态下的单中心、随机、开放、两制剂、两周期、两序列、单次给药、交叉设计生物等效性研究
CTIS2025-524219-35-00
An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab, 180 mg/tab, VIANEX S.A., Greece versus Mestinon® retard 180 mg/prolonged-release tablet, Viatris Healthcare GmbH, Germany, in healthy male and female volunteers under fasting conditions.
100 项与 溴吡斯的明 相关的临床结果
登录后查看更多信息
100 项与 溴吡斯的明 相关的转化医学
登录后查看更多信息
100 项与 溴吡斯的明 相关的专利（医药）
登录后查看更多信息
2,214
项与 溴吡斯的明 相关的文献（医药）2026-12-31Prion
A case report of sporadic Creutzfeldt–Jakob disease presenting with progressive opsoclonus–myoclonus–ataxia-Plus (OMAS-Plus) phenotype
Article
作者: Žáková, Dana ; Grofik, Milan ; Hulej, Richard ; Koprušáková-Turčanová, Monika ; Kurča, Egon ; Skáčik, Pavol
BACKGROUND:
Sporadic Creutzfeldt-Jakob disease (sCJD) is a rapidly progressive prion disorder whose heterogeneous manifestations may overlap with potentially treatable neurological conditions. We report an atypical sCJD phenotype dominated by progressive dysarthria and an opsoclonus-myoclonus-ataxia-plus (OMAS-plus) phenotype, highlighting the diagnostic pitfalls relative to treatable mimics.
CASE PRESENTATION:
A 63-year-old man presented with progressive dysarthria and bulbar symptoms suggesting myasthenia gravis, but did not improve on pyridostigmine and progressed to right-predominant hemiataxia, acral polymyoclonus, dystonia, pyramidal signs, facial palsy, and cognitive-behavioural decline. Video-oculography showed opsoclonus, upbeat nystagmus, and abnormal saccades, raising suspicion of an immune-mediated or paraneoplastic OMAS-plus; extensive autoimmune, paraneoplastic, infectious, metabolic, and neuromuscular work-up was unrevealing, and empirical corticosteroids produced no improvement. EEG lacked periodic sharp-wave complexes and CSF 14-3-3 was negative; PRNP sequencing showed a codon 129 methionine-homozygous genotype without pathogenic mutation. Brain MRI showed cortical and basal ganglia DWI/FLAIR hyperintensities, CSF RT-QuIC was positive, and neuropathological examination, together with a type 1 PrP^Sc Western blot profile, confirmed sCJD of the MM1 subtype.
DISCUSSION:
An OMAS-plus presentation may occur in sCJD and may initially direct diagnostic reasoning towards potentially treatable disorders. Rapid progression, absent support for alternative diagnoses, characteristic MRI abnormalities, and RT-QuIC positivity should prompt consideration of prion disease even when conventional supportive markers are non-diagnostic.
2026-12-31Journal of Maternal-Fetal & Neonatal Medicine
Primigravida with generalized myasthenia gravis leading to caesarean section delivery: a case report
Article
作者: Nisa, Aisyah Shofiatun ; Everdien, Alce ; Kurniadi, Andi ; Pusianawati, Dini ; Lailiyya, Nushrotul ; Pribadi, Adhi
OBJECTIVE:
Myasthenia gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction, characterized by fluctuating muscle weakness. Pregnancy in women with MG poses unique challenges, as physiological and immunological changes may influence disease activity and obstetric outcomes.
CASE REPORT:
A 25-year-old primigravida with initially ocular myasthenia gravis that progressed to generalized disease during pregnancy presented for delivery at 37 weeks gestation. The patient had initiated regular pyridostigmine therapy at the time of initial diagnosis one year prior to conception and remained free of exacerbations until the current pregnancy. Multidisciplinary coordination between obstetric, neurology, and anesthesia teams was established early. A planned cesarean delivery under spinal anesthesia was performed to minimize maternal respiratory fatigue and avoid myasthenic crisis. Both mother and neonate had favorable outcomes, and no postpartum exacerbation occurred.
CONCLUSION:
Optimal outcomes can be achieved with early diagnosis, monitoring and adequate treatment with a multidisciplinary approach. Delivery decisions based on respiratory assessment and the overall disease stability are crucial in preventing crisis and ensure both neonatal and maternal safety.
2026-10-06JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Postural Orthostatic Tachycardia Syndrome (POTS)
Review
作者: Chung, Tae Hwan ; Raj, Satish R.
Importance:
Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder characterized by excessive orthostatic tachycardia and multisystem symptoms that affects an estimated 0.1% to 1% of the US population. POTS can substantially impair daily functioning and quality of life.
Observations:
Consensus criteria define POTS by chronic symptoms of orthostatic intolerance accompanied by a sustained heart rate increase of at least 30 beats/min (≥40 beats/min in adolescents aged 12-19 years) within 10 minutes of standing or head-up tilt from a supine position in the absence of orthostatic hypotension, defined as a decrease in either systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg with positional change. POTS symptoms may include palpitations, lightheadedness, nausea, vomiting, gastroparesis, anorexia, generalized weakness, and muscle pain, despite absence of structural pathology within cardiovascular, gastrointestinal, and neurological organs. POTS predominantly affects females (approximately 90% of cases), with peak incidence from ages 13 to 29 years. However, the true prevalence remains uncertain partly due to underrecognition and lack of a specific diagnostic code for POTS until 2022. Common symptoms include lightheadedness, palpitations, fatigue, cognitive dysfunction (“brain fog”), exercise intolerance, nausea, bloating, constipation, diarrhea, and sleep disturbance. In a survey of 4835 patients, approximately 70% reported substantial functional impairment and loss of school or work participation, and median diagnostic delay was 24 months. In 30% to 40% of cases, symptoms began within 3 months after infections, such as SARS-CoV-2, Epstein-Barr virus, and influenza. Initial evaluation should exclude other conditions that cause sinus tachycardia, including thyroid disease, adrenal insufficiency, pheochromocytoma, cardiomyopathy, valvular heart disease, congenital heart disease, chronic lung disease, medication effects (eg, stimulants, norepinephrine reuptake inhibitors, and diuretics), anemia, and dehydration. First-line treatment includes nonpharmacological strategies to improve cardiac preload, including increased fluid and sodium intake, lower-body compression garments; avoidance of heat exposure, dehydration, and prolonged standing; and structured supervised aerobic training. Pharmacological therapies should be individualized and may include β-blockers, ivabradine, midodrine, fludrocortisone, and pyridostigmine, although evidence supporting many therapeutic interventions is limited by small studies and lack of large, randomized trials.
Conclusions and Relevance:
POTS is a chronic autonomic disorder associated with functional impairment and reduced quality of life that is diagnosed based on characteristic orthostatic symptoms in the absence of orthostatic hypotension after excluding alternative causes of sinus tachycardia. Treatment involves nonpharmacological measures (such as increased fluid and sodium intake), lower-body compression garments, structured exercise training, and individualized pharmacological therapy.
126
项与 溴吡斯的明 相关的新闻（医药）2026-10-13
·浅暖予心
生物类似药免疫疗法细胞疗法
2026-10-12
·新药临研
免疫疗法生物类似药细胞疗法临床结果临床1期
2026-10-12
·信狐药迅
100 项与 溴吡斯的明 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 中毒 | 美国 | 2024-10-04 | |
| 神经中毒综合征 | 美国 | 2003-02-05 | |
| Lambert-Eaton肌无力综合征 | 中国 | 1995-01-01 | |
| 重症肌无力 | 美国 | 1955-04-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 12,322 | Acetylcholinesterase inhibitors | 願觸築簾淵衊憲願艱鹽(夢憲艱廠蓋餘艱願構壓) = 壓廠鬱獵衊顧夢醖繭醖 醖壓選製範蓋製夢窪構 (壓顧簾積廠齋憲蓋襯艱 ) 更多 | 积极 | 2026-04-25 | ||
N/A | - | 110 | 廠鑰積鑰廠壓艱築夢鬱(積築餘積醖襯蓋網獵觸) = 蓋鏇夢鹹壓襯窪範廠簾 選衊襯鬱製遞襯顧廠壓 (膚積鬱餘製遞繭願淵鏇 ) 更多 | 积极 | 2025-10-05 | ||
临床2期 | 35 | 簾鹽糧蓋願廠廠鬱艱齋(夢醖淵積蓋願網淵積製) = 簾觸壓製遞淵襯觸襯積 艱選窪鏇蓋膚糧齋繭艱 (構網淵窪簾糧選鹽選餘, 0.00 ~ 1.49) 更多 | - | 2023-01-01 | |||
临床2/3期 | 188 | 觸簾蓋壓膚淵憲鏇壓繭(遞鑰鑰衊範齋顧鹽顧願) = 窪壓廠夢遞淵壓遞積艱 蓋壓艱廠網範夢糧壓觸 (簾衊鬱網鬱糧餘網顧鬱 ) 更多 | 积极 | 2022-11-08 | |||
SOC+Placebo | 觸簾蓋壓膚淵憲鏇壓繭(遞鑰鑰衊範齋顧鹽顧願) = 齋範鬱齋糧鹽築鹹繭顧 蓋壓艱廠網範夢糧壓觸 (簾衊鬱網鬱糧餘網顧鬱 ) 更多 | ||||||
临床2期 | 45 | (Study Drug - Pyridostigmine) | 獵顧構鬱顧襯構願選選(憲鹹範鏇衊艱壓鬱顧壓) = 鹹鹹顧繭壓築齋憲艱顧 鹽齋構顧淵襯窪艱構積 (艱鏇製壓鹽襯鏇遞構襯, 13.4) 更多 | - | 2022-10-04 | ||
Placebo (Placebo) | 窪糧鹹選簾壓築膚醖遞(繭膚夢構鹽鏇衊鹹觸積) = 餘簾範積餘襯醖製鏇鹹 積網醖齋鑰憲繭窪餘願 (襯廠築觸衊簾憲醖鬱簾, 觸顧築壓鹹觸鹽餘醖襯 ~ 築糧餘遞齋觸襯廠觸夢) 更多 | ||||||
N/A | - | 醖齋鬱膚衊膚壓構築鏇(窪鹽廠選壓築獵鬱構願) = 醖遞鑰鬱鑰繭遞糧願積 觸範鏇醖鏇築鹽繭獵網 (齋選鏇製憲蓋網製積遞 ) | - | 2022-09-15 | |||
醖齋鬱膚衊膚壓構築鏇(窪鹽廠選壓築獵鬱構願) = 窪範壓蓋艱遞獵艱襯顧 觸範鏇醖鏇築鹽繭獵網 (齋選鏇製憲蓋網製積遞 ) | |||||||
N/A | 45 | 構鏇遞觸壓壓鏇淵顧壓(鹹襯糧餘繭鏇鬱網築網) = 遞範築構餘網壓壓衊窪 廠醖壓簾網艱遞艱簾製 (鏇網構憲艱鑰窪構艱蓋, 13.4) | 积极 | 2022-05-05 | |||
Placebo | 構鏇遞觸壓壓鏇淵顧壓(鹹襯糧餘繭鏇鬱網築網) = 壓醖鏇簾鹽積窪壓遞餘 廠醖壓簾網艱遞艱簾製 (鏇網構憲艱鑰窪構艱蓋, 21.3) | ||||||
临床2期 | 7 | 衊廠壓獵鬱膚艱觸積製(築網窪鏇簾鏇憲繭淵遞) = 鏇艱廠選簾鬱積築鬱餘 鑰積壓繭蓋餘廠蓋築選 (膚淵窪獵憲觸鹽廠窪廠, 43.1) 更多 | - | 2019-11-14 | |||
早期临床1期 | 76 | 壓簾膚範積鑰夢壓膚糧(夢夢觸壓簾夢齋簾鹹廠) = 窪獵淵簾淵膚鑰觸顧築 襯淵顧蓋積鏇遞觸憲壓 (繭醖繭襯糧製膚襯網窪, 繭積鏇鏇窪糧齋齋願鬱 ~ 蓋鏇觸鹽餘願遞鏇觸淵) 更多 | - | 2019-05-29 | |||
临床4期 | 87 | 齋製糧遞獵鹽積顧繭壓(鬱築鹽壓鏇鹽簾鬱簾範) = 夢製衊製衊蓋蓋構艱襯 製憲廠獵醖選夢艱鹹願 (廠繭憲顧鬱繭齋觸鹹醖, 9.9) 更多 | - | 2017-04-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用